Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2025-12-08 Capital/Financing Update
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Initial Allotment of Placement Shares 2 pages 186.5KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 9 December 2025 from InhaleRx Ltd regarding the issuance of new ordinary shares as part of a capital raise. It details the number of shares issued, the issue price, the total amount raised, the structure of the placement (including tranches and options), and mentions shareholder approval requirements under ASX Listing Rules. The content focuses on fundraising activities and changes in the company's capital structure. There are no financial statements, quarterly or annual results, or management discussion of financial performance. The document length is 3890 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of a Capital/Financing Update (CAP).
2025-12-08 English
Application for quotation of securities - IRX 6 pages 18.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement by Inhalerx Limited regarding the application for quotation of securities on the ASX. It details the number and type of securities to be quoted, issue dates, and references a previous Appendix 3B announcement about the securities issuance. The document is an official application for listing new securities rather than a report on financial performance or a detailed financial statement. It is not an annual report, earnings release, or management report. It is also not a regulatory certification or a voting result announcement. The document fits the category of Share Issue/Capital Change as it concerns the quotation of newly issued shares and related securities on the exchange.
2025-12-08 English
Dispatch of Entitlement Offer Prospectus 2 pages 190.9KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Dispatch of Entitlement Offer Prospectus' and announces the dispatch of the Entitlement Offer Prospectus and accompanying forms to shareholders. It provides a timetable for the offer, including opening and closing dates, and mentions the results announcement and subsequent share issuance. The document is an announcement about the start of a capital raising process via an entitlement offer, not the offer prospectus itself or detailed financial data. The length is 3081 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Capital/Financing Update (CAP), as it relates to company fundraising activities and capital structure changes.
2025-12-04 English
Entitlement Offer - Ineligible Shareholders Letter 2 pages 214.4KB
Capital/Financing Update Classification · 95% confidence The document is a letter dated 5 December 2025 from InhaleRx Limited informing certain shareholders that they are ineligible to participate in a non-renounceable pro-rata entitlement offer. It details the terms of the entitlement offer, references the prospectus dated 26 November 2025, and explains the legal and regulatory reasons for excluding shareholders outside Australia and New Zealand. The document is an announcement related to a capital raising event (entitlement offer) and discusses the offer's terms, eligibility, and procedures. It does not contain financial statements or detailed financial analysis but rather communicates the capital raising activity and shareholder eligibility. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-12-04 English
$12.6m Facility to Drive SRX-25 Development 3 pages 213.3KB
Capital/Financing Update Classification · 95% confidence The document is an announcement about InhaleRx securing additional funding of $12.6 million from Linlithgow Family Office to support the development of their drug SRX-25. It details the terms of the funding facility, the purpose of the funds, and the company's plans for clinical trials. There are no financial statements, quarterly or annual results, or detailed financial performance data. The document focuses on capital raising and financing activities related to drug development. It is not a full financial report, earnings release, or management discussion. The content aligns with updates on company fundraising and capital structure changes, which fits the Capital/Financing Update (CAP) category. The document length is sufficient and contains substantive information about financing, not just a brief announcement or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2025-12-03 English
Drug Development Pipeline Bolstered and Capital Raise 5 pages 238.6KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from InhaleRx Ltd about the addition of a new drug asset (SRX-25) to its development pipeline, including clinical development plans, regulatory pathway (FDA 505(b)(2)), and funding details. It also includes a capital raising announcement involving a placement and a rights issue, with specifics on share issuance, pricing, and use of funds. The content focuses on financing activities and strategic development updates rather than financial results, management changes, or regulatory certifications. The presence of detailed capital raising information and share issuance terms indicates this is a Capital/Financing Update. The document length and detail confirm it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-11-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.